[Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality.
• Molecular targeted therapies, focusing on genetic alterations like EGFR mutations and EML4-ALK fusions, represent a significant advancement in NSCLC treatment.
• Historically, EML4-ALK fusions and EGFR mutations were considered mutually exclusive in NSCLC.

Purpose of the Study:

• To review the incidence and molecular characteristics of EML4-ALK fusion genes in NSCLC.
• To review the incidence and molecular characteristics of EGFR mutations in NSCLC.
• To summarize clinical features of NSCLC patients with concomitant EML4-ALK fusion and EGFR mutation.

Main Methods:

• Literature review of published studies on NSCLC.
• Analysis of incidence and molecular structure of EML4-ALK fusions.
• Analysis of incidence and molecular structure of EGFR mutations.
• Summary of clinical data for patients with co-occurring alterations.

Main Results:

• Recent reports indicate a continuous increase in documented cases of NSCLC patients with both EML4-ALK fusion and EGFR mutation.
• This review consolidates information on the molecular subtypes and prevalence of these co-occurring genetic alterations.
• Clinical features associated with concomitant EML4-ALK fusion and EGFR mutation in NSCLC are detailed.

Conclusions:

• The co-occurrence of EML4-ALK fusion and EGFR mutation in NSCLC is being increasingly reported.
• Understanding these concomitant genetic profiles is crucial for refining NSCLC diagnosis and treatment strategies.
• Further research is warranted to elucidate the clinical implications and therapeutic approaches for NSCLC patients with dual alterations.